FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947122960> ?p ?o ?g. }

• W2947122960 endingPage "76" @default.
• W2947122960 startingPage "69" @default.
• W2947122960 abstract "Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (TD). The KINECT 3 study (NCT02274558) evaluated the effects of VBZ on TD in subjects with schizophrenia/schizoaffective disorder (SCHZ) or mood disorder (mood disorder presented separately) who received up to 48 weeks of treatment.KINECT 3 included: 6-week, double-blind, placebo (PBO)-controlled (DBPC) period (205 completers); 42-week VBZ extension (VE) period (124 completers): 4-week washout period (121 completers). Subjects entering the DBPC were randomized 1:1:1 to once-daily VBZ 80 mg, VBZ 40 mg, or PBO; stable concomitant antipsychotic medication regimens were allowed. Subjects completing the DBPC and entering the VE period were re-randomized (blinded) 1:1 from PBO to VBZ (80 or 40 mg) or continued VBZ treatment at the same dose. Efficacy assessments included: mean changes from baseline in Abnormal Involuntary Movement Scale (AIMS) total score (items 1-7); mean Clinical Global Impression of Change (CGI-TD) scores; AIMS responders (subjects with ≥50% score reduction from baseline): and CGI-TD responders (subjects with score ≤2 [much improved or very much improved]). Treatment effect sizes (Cohen's d) and numbers needed to treat (NNTs) were analyzed for DBPC outcomes.Efficacy analyses were conducted in 148 subjects (DBPC) and 125 subjects (VE) with SCHZ. At Week 6 (end of DBPC), AIMS mean score improvements were greater in the VBZ groups (in a dose-related pattern) than in the PBO group (80 mg, -2.9, d = 0.88; 40 mg, -1.6, d = 0.52; PBO, +0.3). AIMS score changes at Week 48 (end of VE) showed continued TD improvement during long-term VBZ treatment (80 mg, -4.2; 40 mg, -2.5). By Week 52 (end of washout), AIMS scores were returning toward baseline levels, indicating re-emergence of TD. CGI-TD mean scores were as follows: Week 6 (80 mg, 3.0, d = 0.11; 40 mg, 2.9, d = 0.23; PBO, 3.2), Week 48 (80 mg, 2.2; 40 mg, 2.4), Week 52 (80 mg, 3.4; 40 mg, 3.3). AIMS responder rates (≥50% score reduction) were greater with VBZ than with PBO at Week 6 (80 mg, 40.9%, NNT = 4; 40 mg, 26.2%, NNT = 6; PBO, 9.3%), were increased at Week 48 (80 mg, 50.0%; 40 mg, 26.2%), and decreased after VBZ washout (80 mg, 21.6%; 40 mg, 9.5%). CGI-TD responder rates followed a similar pattern: Week 6 (80 mg, 29.5%, NNT = 17; 40 mg, 33.3%, NNT = 10; PBO, 23.3%), Week 48 (80 mg, 73.7%; 40 mg, 58.1%), Week 52 (80 mg, 29.7%; 40 mg, 33.3%).Sustained TD improvements were found in subjects with SCHZ who received up to 48 weeks of VBZ, with TD reverting toward baseline when assessed 4 weeks after treatment withdrawal. Together with results from mood disorder subjects and the long-term safety profile (presented separately), these results indicate that long-term VBZ can be beneficial for managing TD regardless of psychiatric diagnosis category." @default.
• W2947122960 created "2019-06-07" @default.
• W2947122960 creator A5004031088 @default.
• W2947122960 creator A5021418387 @default.
• W2947122960 creator A5036151807 @default.
• W2947122960 creator A5051911390 @default.
• W2947122960 creator A5056944189 @default.
• W2947122960 date "2017-08-01" @default.
• W2947122960 modified "2023-09-23" @default.
• W2947122960 title "Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder." @default.
• W2947122960 cites W2337201199 @default.
• W2947122960 cites W2598837636 @default.
• W2947122960 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5546553" @default.
• W2947122960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28839342" @default.
• W2947122960 hasPublicationYear "2017" @default.
• W2947122960 type Work @default.
• W2947122960 sameAs 2947122960 @default.
• W2947122960 citedByCount "8" @default.
• W2947122960 countsByYear W29471229602018 @default.
• W2947122960 countsByYear W29471229602019 @default.
• W2947122960 countsByYear W29471229602021 @default.
• W2947122960 countsByYear W29471229602022 @default.
• W2947122960 crossrefType "journal-article" @default.
• W2947122960 hasAuthorship W2947122960A5004031088 @default.
• W2947122960 hasAuthorship W2947122960A5021418387 @default.
• W2947122960 hasAuthorship W2947122960A5036151807 @default.
• W2947122960 hasAuthorship W2947122960A5051911390 @default.
• W2947122960 hasAuthorship W2947122960A5056944189 @default.
• W2947122960 hasConcept C118552586 @default.
• W2947122960 hasConcept C126322002 @default.
• W2947122960 hasConcept C142724271 @default.
• W2947122960 hasConcept C15744967 @default.
• W2947122960 hasConcept C168563851 @default.
• W2947122960 hasConcept C204787440 @default.
• W2947122960 hasConcept C27081682 @default.
• W2947122960 hasConcept C2776000289 @default.
• W2947122960 hasConcept C2776412080 @default.
• W2947122960 hasConcept C2779134260 @default.
• W2947122960 hasConcept C2779158372 @default.
• W2947122960 hasConcept C2779727114 @default.
• W2947122960 hasConcept C2779734285 @default.
• W2947122960 hasConcept C2780325297 @default.
• W2947122960 hasConcept C2780405171 @default.
• W2947122960 hasConcept C2780494398 @default.
• W2947122960 hasConcept C2780616385 @default.
• W2947122960 hasConcept C71924100 @default.
• W2947122960 hasConceptScore W2947122960C118552586 @default.
• W2947122960 hasConceptScore W2947122960C126322002 @default.
• W2947122960 hasConceptScore W2947122960C142724271 @default.
• W2947122960 hasConceptScore W2947122960C15744967 @default.
• W2947122960 hasConceptScore W2947122960C168563851 @default.
• W2947122960 hasConceptScore W2947122960C204787440 @default.
• W2947122960 hasConceptScore W2947122960C27081682 @default.
• W2947122960 hasConceptScore W2947122960C2776000289 @default.
• W2947122960 hasConceptScore W2947122960C2776412080 @default.
• W2947122960 hasConceptScore W2947122960C2779134260 @default.
• W2947122960 hasConceptScore W2947122960C2779158372 @default.
• W2947122960 hasConceptScore W2947122960C2779727114 @default.
• W2947122960 hasConceptScore W2947122960C2779734285 @default.
• W2947122960 hasConceptScore W2947122960C2780325297 @default.
• W2947122960 hasConceptScore W2947122960C2780405171 @default.
• W2947122960 hasConceptScore W2947122960C2780494398 @default.
• W2947122960 hasConceptScore W2947122960C2780616385 @default.
• W2947122960 hasConceptScore W2947122960C71924100 @default.
• W2947122960 hasIssue "3" @default.
• W2947122960 hasLocation W29471229601 @default.
• W2947122960 hasOpenAccess W2947122960 @default.
• W2947122960 hasPrimaryLocation W29471229601 @default.
• W2947122960 hasRelatedWork W129568245 @default.
• W2947122960 hasRelatedWork W1513287240 @default.
• W2947122960 hasRelatedWork W1605318477 @default.
• W2947122960 hasRelatedWork W1847831565 @default.
• W2947122960 hasRelatedWork W1990712459 @default.
• W2947122960 hasRelatedWork W2097120061 @default.
• W2947122960 hasRelatedWork W2143041619 @default.
• W2947122960 hasRelatedWork W2283053330 @default.
• W2947122960 hasRelatedWork W2947122960 @default.
• W2947122960 hasRelatedWork W11955568 @default.
• W2947122960 hasVolume "47" @default.
• W2947122960 isParatext "false" @default.
• W2947122960 isRetracted "false" @default.
• W2947122960 magId "2947122960" @default.
• W2947122960 workType "article" @default.